TIMOLOL

Search structure
Trade Names:
Synonyms:
Status: Approved (1978)
Entry Type: Small molecule
Molecule Category: Parent
ATC: C07AA06
UNII: 5JKY92S7BR

Structure
InChI Key BLJRIMJGRPQVNF-JTQLQIEISA-N
Smile CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
InChI
InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H24N4O3S
Molecular Weight 316.43
AlogP 0.5
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 6.0
Polar Surface Area 79.74
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 21.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Beta-1 adrenergic receptor antagonist DailyMed
Primary Target
β2-adrenoceptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6
- 11000 - - -
Ion channel Voltage-gated ion channel Voltage-gated sodium channel
- - - - 8
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor
- - 0-0 3-631 -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Serotonin receptor
- - - 617 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - - 39

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Exfoliation Syndrome 3 D017889 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Wet Macular Degeneration 2 D057135 ClinicalTrials
Telangiectasia, Hereditary Hemorrhagic 2 D013683 ClinicalTrials
Wounds and Injuries 2 D014947 ClinicalTrials
Migraine Disorders 2 D008881 ClinicalTrials
Varicose Ulcer 2 D014647 ClinicalTrials
Hemangioma 2 D006391 ClinicalTrials

Related Entries

MCS

Side Effects from Label

Side effects Relative Frequency (%) Labels
Eye disorders Visual impairment 25.0
General disorders and administration site conditions Pain 23.6
General disorders and administration site conditions Pain 11.6
Cardiac disorders Bradycardia 9.1
Eye disorders Conjunctival hyperaemia 8.2
Cardiac disorders Cardiac failure 8.0
Gastrointestinal disorders Nausea 8.0
General disorders and administration site conditions Peripheral coldness 8.0
Cardiac disorders Cardiac failure
Eye disorders Visual impairment 6.9
Cardiac disorders Dizziness 6.0
Gastrointestinal disorders Nausea
Eye disorders Vision blurred 6.0
General disorders and administration site conditions Sensation of foreign body 5.3
General disorders and administration site conditions Asthenia 5.0
General disorders and administration site conditions Fatigue 5.0
Eye disorders Vision blurred 4.1
Cardiac disorders Dizziness
Eye disorders Conjunctivitis 3.5
Eye disorders Keratitis 3.5
General disorders and administration site conditions Asthenia 3.4
General disorders and administration site conditions Fatigue 3.4
Cardiac disorders Cardiac failure 3.0
Vascular disorders Hypotension 3.0
Vascular disorders Intermittent claudication
Vascular disorders Intermittent claudication 3.0
General disorders and administration site conditions Discomfort 2.9
Eye disorders Conjunctival hyperaemia 2.5
Cardiac disorders Dizziness 2.3
Respiratory, thoracic and mediastinal disorders Bronchial obstruction 2.0
Cardiac disorders Cardiac failure
Vascular disorders Hypotension
Cardiac disorders Pulmonary oedema 2.0
Nervous system disorders Headache
Cardiac disorders Dyspnoea 1.7
Nervous system disorders Headache 1.7
Cardiac disorders Dizziness
General disorders and administration site conditions Oedema
Cardiac disorders Arrhythmia 1.1
Eye disorders Conjunctivitis 1.1
Eye disorders Eye irritation 1.1
Eye disorders Keratitis 1.1
Skin and subcutaneous tissue disorders Pruritus 1.1
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Asthenia 1.0
Cardiac disorders Atrioventricular block
Cardiac disorders Atrioventricular block 1.0
Respiratory, thoracic and mediastinal disorders Bronchial obstruction
Respiratory, thoracic and mediastinal disorders Bronchial obstruction 1.0
Product issues Device capturing issue
Product issues Device capturing issue 1.0
Cardiac disorders Dizziness 1.0
General disorders and administration site conditions Fatigue
General disorders and administration site conditions Fatigue 1.0
Vascular disorders Hypotension
Vascular disorders Intermittent claudication
Vascular disorders Intermittent claudication 1.0
Gastrointestinal disorders Nausea
Gastrointestinal disorders Nausea 1.0
General disorders and administration site conditions Peripheral coldness
General disorders and administration site conditions Peripheral coldness 1.0
Cardiac disorders Pulmonary oedema
Cardiac disorders Pulmonary oedema 1.0
Cardiac disorders Sinoatrial block
Cardiac disorders Sinoatrial block 1.0
Cardiac disorders Arrhythmia
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Asthenia 0.6
Immune system disorders Bronchospasm 0.6
Cardiac disorders Chest pain 0.6
Psychiatric disorders Disturbance in sexual arousal 0.6
Cardiac disorders Dizziness 0.6
Gastrointestinal disorders Dyspepsia
Gastrointestinal disorders Dyspepsia 0.6
Cardiac disorders Dyspnoea
Eye disorders Eye irritation
General disorders and administration site conditions Fatigue
Psychiatric disorders Libido decreased 0.6
Nervous system disorders Loss of consciousness 0.6
Gastrointestinal disorders Nausea 0.6
General disorders and administration site conditions Oedema 0.6
Nervous system disorders Paraesthesia 0.6
Respiratory, thoracic and mediastinal disorders Rales 0.6
Vascular disorders Shock 0.6
Cardiac disorders Syncope 0.6
Ear and labyrinth disorders Tinnitus 0.6
Ear and labyrinth disorders Vertigo 0.6

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
18.1
Nervous system disorders
14.66
Cardiac disorders
12.07
General disorders and administration site conditions
12.07
Respiratory, thoracic and mediastinal disorders
11.21
Vascular disorders
6.9
Investigations
5.17
Injury, poisoning and procedural complications
4.31
Skin and subcutaneous tissue disorders
3.45
Psychiatric disorders
2.59

Cross References

Resources Reference
CAS NUMBER 26839-75-8
ChEBI 9599
ChEMBL CHEMBL499
DrugBank DB00373
DrugCentral 4061
EPA CompTox DTXSID4023674
FDA SRS 5JKY92S7BR
Guide to Pharmacology 565
KEGG C07141
PDB TIM
PharmGKB PA451690
PubChem 62933
SureChEMBL SCHEMBL4912
ZINC ZINC000000002176
CONTENTS